UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

You may be eligible if

• Relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL).
• Relapsed or refractory mature T-cell lymphoma to include peripheral T-cell lymphoma unspecified and the following "specified" mature T-cell lymphomas:
• Adult T-cell lymphoma; Extranodal natural killer (NK)/T-cell lymphoma,
• nasal type; Enteropathy-type T-cell lymphoma;
• Hepatosplenic T-cell lymphoma;
• Subcutaneous panniculitis-like T-cell lymphoma;
• Angioimmunoblastic T-cell lymphoma.
• All patients should have evaluable or measurable disease on entry to study.
• Histology confirmed by Laboratory of Pathology, National Cancer Institute (NCI).
• Performance Status Eastern Cooperative Oncology Group (ECOG) less than or equal to 2.
• Age 7 years or older.
• Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than 50 ml/min for patients at least 18 years.
• Pediatric patients should have maximum serum creatinine by age as follows:
• Less than age 7 and less than or equal to age 10 may have a Maximum Serum Creatinine of 1.0 mg/dl
• Less than age10 and less than or equal to age 15 may have a Maximum Serum Creatinine of 1.2 mg/dl
• Age 15 years or older may have a Maximum Serum Creatinine of 1.5 mg/dl
• Alternatively, pediatric patients should have a creatinine clearance of greater than 50 m1/min/1.73m\^2.
• Total bilirubin less than 1.5 x upper limit of normal (ULN) (patients with elevation of total bilirubin consistent with Gilbert's disease are eligible providing they have a normal direct bilirubin);
• aspartate aminotransferase (AST) less than or equal to 2.5 x ULN;
• absolute neutrophil count (ANC) greater than 500/mm\^3;
• and platelet greater than or equal to 50,000/mm\^3;
• unless hematological impairment due to organ involvement by lymphoma.
• Provides signed informed consent.
• Not pregnant or nursing. This drug has unknown effects in pregnancy and on young infants/children.
• Human immunodeficiency virus (HIV) negative.
• Willing to use contraception and continue for at least 8 weeks following the last treatment.
• No active central nervous system (CNS) lymphoma.
• Patients should not have received systemic cytotoxic chemotherapy within 3 weeks of study entry.
• Have recovered from the toxic effects of prior therapy to a grade less than or equal to 1.
• No history of diabetes mellitus requiring insulin treatment.
• No symptomatic pulmonary disease.
• No evidence of symptomatic cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, exertional angina pectoris, cardiac arrhythmia).
• Patients may not be concurrently receiving any other investigational agents.
• Not a candidate for potentially curative (i.e. transplant) treatment at the time of study entry or the patient has a window of opportunity to receive UCN-01 before a transplant. Patients are required to have considered a transplant. If, having done this, they refuse it, decide against it or decide to wait, they would be eligible for this study.